Malignant T-cell-amplified sequence 1 (MCTS1)

Malignant T-cell-amplified sequence 1 (MCTS1) is an oncoprotein and translation regulator that forms a complex with the density-regulated re-initiation and release factor (DENR), promoting translation reinitiation on mRNA and thus altering protein synthesis profiles[4][5][6]. It plays multiple roles in tumorigenesis: it accelerates cell cycle progression (notably the G1/S transition), promotes cell proliferation and invasion, and facilitates metastasis by regulating processes such as the epithelial-mesenchymal transition (EMT)[1]. MCTS1 overexpression reduces p53 and p21 protein levels, increases cyclin D/CDK4/6 complexes, and modulates signaling cascades including ERK, AKT, and Src pathways, as well as cytokine responses (e.g., IL-6/STAT3), resulting in enhanced tumor aggressiveness and chemoresistance[1][3]. High expression correlates with poor prognosis in various cancer types, suggesting potential value as a prognostic biomarker[3]. While no direct inhibitors currently exist, its central role in malignancy and translation regulation makes it a promising candidate for therapeutic intervention[2][3].

Other names

MCT1MCT-1Multiple copies T-cell malignanciesMultiple copies in T-cell lymphoma-1IMD118MCTS1 re-initiation and release factorMalignant T-cell amplified sequence 1

No direct-acting drugs; indirect modulation through downstream pathways (e.g., modulation of p53 pathway, interaction with translation machinery, impact on cyclin D/CDK complexes, regulation of susceptibility to apoptosis inducers). Agents targeting associated pathways (e.g., PARP inhibitors, IL-6 pathway inhibition) may have altered effects based on MCTS1 status.